The kit, developed by BGI Patho-Genesis Pharmaceutical Technology, is designed to construct a metagenomic sequencing library directly from clinical samples.
The wastewater analytics firm will work with the two government agencies to analyze samples from treatment plants across the US for SARS-CoV-2 viral elements.
The company's HCCscreen assay will be used in a liver cancer screening public health initiative, generating real-world data on the test's clinical validity and impact.
The next-generation sequencing-based panel comprises more than 50 genes and disorders known to cause hereditary anemias, such as pyruvate kinase deficiency.
The RT-PCR-based test was first authorized earlier this year for the detection of SARS-CoV-2 nucleic acid in specimens collected by a healthcare provider.
The company said it will use proceeds from the round, which was led by Casdin Capital, to expand and commercialize its SomaScan platform and SomaSignal tests.
An integrated proteogenomic analysis led to previously unappreciated treatment targets or prognostic markers in craniopharyngioma, high-grade glioma, and other tumor types.
The FDA also reissued Emergency Use Authorizations for SARS-CoV-2 tests from Roche and Express Gene to reflect their permitted use with additional sample types.
The alliance of hospitals, research groups, and academic institutes is tasked with implementing clinical genomics programs in Australia's state of Victoria.
For the three months ended Oct. 31, revenues rose to $1.48 billion from $1.37 billion in Q4 2019, beating the average Wall Street estimate of $1.4 billion.
The Warsaw, Poland-based firm has secured nearly €20 million ($23.7 million) this year to advance its PCR One point-of-care molecular diagnostic system.
Exome array-wide association and rare variant-focused genome-wide association meta-analyses led to 87 rare variants with ties to one or more blood pressure traits.
